MBX Biosciences, Inc. (MBX)
NasdaqGS · Biotechnology
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
MBX Biosciences, Inc. is trading at $55.87, up 2.44% on the session. The 50 day average sits at $57.82 and the 200 day at $45.58, which puts the stock in a uptrend. RSI is at 53.8, which reads as neutral, and MACD is bullish crossover. Volume is above average.
The nearest support is around $52.32 with resistance near $56.20, so that band frames the current range. Average daily movement is roughly $3.42, or about 6.1% of the share price, which is what any stop placement has to allow for. The overall health score of 52 out of 100 combines a trend score of 53, momentum of 65 and a risk score of 34.
Technical indicators
AI trade signals on MBX
All signals| Date | Setup | Entry | Target | Stop | R:R | Status |
|---|---|---|---|---|---|---|
| Oct 13 | Bounce | ••.•• | ••.•• | ••.•• | 1.63:1 | Expired |
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Company website